2. Academic Validation
  3. Novel immunotherapeutic drugs for the treatment of lung cancer

Novel immunotherapeutic drugs for the treatment of lung cancer

  • Curr Opin Oncol. 2022 Jan 1;34(1):89-94. doi: 10.1097/CCO.0000000000000800.
Ling Peng 1,  Zibing Wang 2,  Justin Stebbing 3,  Zhentao Yu 4
Affiliations

Affiliations

  • 1 Department of Respiratory Disease, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province.
  • 2 Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China.
  • 3 Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.
  • 4 Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
PMID: 34636350 DOI: 10.1097/CCO.0000000000000800
Abstract

Purpose of review: Cancer cells evade immune surveillance partly due to the immunosuppressive features of the tumor microenvironment (TME). Currently approved immuno-oncology drugs for the treatment of lung Cancer are aimed to inhibit immune checkpoints, such as programmed death protein-1 (PD-1), PD ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4. Despite these, researchers are currently racing to create the optimal Cancer Immunotherapy treatments.

Recent findings: Novel immunotherapeutic drugs mainly act on activated immune cells and exert their therapeutic effects by enhancing antitumor responses. In this article, we review new therapies for the treatment of lung Cancer that enhance T cell priming, remove coinhibitory signals, supply costimulatory signals and condition the TME.

Summary: As more immunotherapeutic targets are in studies, designing multimodal strategies to provide greater efficacy with lower toxicity will be necessary.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99640
    AntiCD40 Agonistic Monoclonal Antibody